A critical aspect of Lall’s role in US-India military trade relations is his focus on technology transfer. (Wikipedia) Dr Vivek Lall, Chief Executive of General Atomics Global Corporation ...
The diagnostics chain is currently expanding into tier-three and tier-four markets and is holding off on price increases to ...
Hosted on MSN17d
Dr. Lal PathLabs Q3 results FY 2025 Date and Time: 3rd interim dividend in pipeline! Quarterly earnings schedule of BSE 500 firmDr. Lal PathLabs shares dropped 2 per cent during the intraday session on Friday. Around 2:40 PM, shares were trading at Rs 2818.60 apiece, against the scrip's opening at Rs 2880 apiece. Dr. Lal ...
Dr Lal Pathlabs, India’s largest diagnostic chain, posted a 19.3 per cent rise in profit after tax to Rs 98 crore for Q3FY25 ...
India's Dr Lal Path Labs reported a 19% jump in its third-quarter profit on Thursday, led by continued demand for its bundle test offerings, sending its shares 3% higher. The company's consolidated ...
Dr Lal PathLabs has approved a third interim dividend of ₹6 per equity share, which is 60% on a face value of ₹10 each, for ...
Dr Lal Pathlabs Ltd EBITDA grew 9.5% YoY to ₹154 crore, though margins contracted slightly to 25.8% from 26.1% last year ...
Jan 30 (Reuters) - India's Dr Lal Path Labs (DLPA.NS), opens new tab reported a 19% jump in its third-quarter profit on Thursday, led by continued demand for its bundle test offerings, sending its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback